Brett Ewald has over 15 years of oncology experience within pharma, biotech, and academia, with expertise in early and late stage clinical development, business development, alliance management, and portfolio management. He joined DNAtrix from Novartis Oncology, where he had increasing roles of responsibility and focused on accelerating early stage clinical programs into late stage development. Brett has contributed to the clinical development of many agents, including approved drugs, BRAFTOVI (encorafenib) and PIQRAY (alpelisib). Prior to Novartis, he focused on translational research in the Department of Experimental Therapeutics at MD Anderson Cancer Center, identifying novel ways to target DNA damage repair pathways for the treatment of leukemia. Brett holds a PhD in Pharmacology from The University of Texas Health Science Center, as well as BS and BA degrees in Biology and Economics from Villanova University.